Bluejay Diagnostics implemented a 1-for-4 reverse stock split of its common stock, reducing outstanding shares from approximately 4.47 million to roughly 1.12 million. The transaction became effective at 12:01 a.m. Eastern Time on November 3, 2026, with trading resuming on the Nasdaq Capital Market under the existing symbol BJDX and a new CUSIP number. Fractional shares are cashed out rather than issued. The company operates in the medical diagnostics industry, developing near-patient testing systems for sepsis triage.
